RCUS Stock Overview
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arcus Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.68 |
| 52 Week High | US$25.47 |
| 52 Week Low | US$12.95 |
| Beta | 0.85 |
| 1 Month Change | -10.65% |
| 3 Month Change | -3.74% |
| 1 Year Change | -20.39% |
| 3 Year Change | -57.74% |
| 5 Year Change | 51.03% |
| Change since IPO | -13.65% |
Recent News & Updates
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Recent updates
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Jan 07Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically
Nov 25Analysts Just Shaved Their Arcus Biosciences, Inc. (NYSE:RCUS) Forecasts Dramatically
Aug 08Need To Know: Analysts Are Much More Bullish On Arcus Biosciences, Inc. (NYSE:RCUS) Revenues
Jun 26Shareholder Returns
| RCUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.5% | -2.5% | -3.2% |
| 1Y | -20.4% | -3.7% | 19.3% |
Return vs Industry: RCUS underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: RCUS underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| RCUS volatility | |
|---|---|
| RCUS Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RCUS's share price has been volatile over the past 3 months.
Volatility Over Time: RCUS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 577 | Terry Rosen | www.arcusbio.com |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease.
Arcus Biosciences, Inc. Fundamentals Summary
| RCUS fundamental statistics | |
|---|---|
| Market cap | US$1.33b |
| Earnings (TTM) | -US$307.00m |
| Revenue (TTM) | US$117.00m |
11.4x
P/S Ratio-4.3x
P/E RatioIs RCUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCUS income statement (TTM) | |
|---|---|
| Revenue | US$117.00m |
| Cost of Revenue | US$35.00m |
| Gross Profit | US$82.00m |
| Other Expenses | US$389.00m |
| Earnings | -US$307.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.38 |
| Gross Margin | 70.09% |
| Net Profit Margin | -262.39% |
| Debt/Equity Ratio | 0% |
How did RCUS perform over the long term?
See historical performance and comparison